Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of

Event · Earnings
Original reporting
Published Nov 13, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TVRD
Neutral
medium confidence
Mentioned
$TVRD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TVRDNeutralMed
01

Why it matters

The report provides the first public financial numbers for Q3 2026 and updates on two key clinical programs, offering fresh data for traders.

02

Market read

Primary disclosure of earnings and pipeline milestones for a micro‑cap biotech; modest trading relevance.

03

What to watch

Potential funding needs and IND clearance risk for TTI-109 could constrain near‑term execution.

Relevance 7/10Novelty 6/10Timing: today

Background

The filing is a standard SEC Form 8‑K reporting quarterly results for Tvardi Therapeutics, a clinical‑stage biotech focused on STAT3 inhibition.

Company-level read

Ticker impact

$TVRDNeutralMedium confidence
Context

TVRD disclosed Q3 2026 results with a net loss of $6.1M, cash of $22.3M and progress on its TTI-109 ulcerative colitis program and TTI-101 hepatocellular carcinoma trial.

Expected impact

likely modest downside as investors price the loss and cash position

Evidence & confidence

Losses are larger than prior year but cash is sufficient to Q3 2027; clinical milestones drive future upside.

Market effects

Biotech sector may see modest pressure as a microcap reports a loss, but the clinical updates could spark interest in STAT3‑targeted therapies.

Limited to US biotech investors; no broader regional effect.

Low global impact; relevance confined to investors tracking early‑stage biotech pipelines.

Counterpoint

Despite the loss, the cash runway and upcoming trial readouts could make the stock a long‑term upside play.

Key entities

  • Tvardi Therapeutics

    Clinical‑stage biopharma developing STAT3 inhibitors.

  • Imran Alibhai

    CEO of Tvardi Therapeutics, quoted on program progress.

Related articles

$TVRDMed

Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.

$TVRDMed

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.

$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.